Skip to main content
SpringerLink
Log in

Emerging Endoscopic Therapies for Weight Loss

  • Chapter
  • First Online:
Gastrointestinal Interventional Endoscopy

Abstract

The prevalence of obesity and metabolic disease continues to rise in the United States and around the world. Efforts to combat this growing pandemic have utilized a multipronged strategy, including promoting public education, implementing public health measures, and focusing on a multidisciplinary treatment approach integrating nutrition, psychology, medicine, and surgery. Another component of this multipronged strategy has been the development of endoscopic therapeutic options less invasive than surgery. Currently, there are four FDA-approved devices, including three intra-gastric balloons and an aspiration device, which are discussed in a prior chapter. This chapter will focus on emerging endoscopic interventions for weight loss and metabolic therapies currently in development and/or undergoing clinical trials.

Disclosures

Thomas J. Wang: None.

Marvin Ryou: Covidien/Medtronic (consultant); GI Windows (co-founder).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Center for Health Statistics. National Health and Nutrition Examination Survey. 2014. URL: http://www.cdc.gov/nchs/nhanes.htm [accessed 2014-09-08][WebCite Cache]. 2014.

  2. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28(5):w822–31.

    Article  Google Scholar 

  3. Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012;31(1):219–30.

    Article  Google Scholar 

  4. Ma IT, Madura JA. Gastrointestinal complications after bariatric surgery. Gastroenterol Hepatol. 2015;11(8):526.

    Google Scholar 

  5. Ryou M, McQuaid KR, Thompson CC, Edmundowicz S, Mergener K, Force AE. ASGE EndoVators Summit: defining the role and value of endoscopic therapies in obesity management. Obesity surgery. 2018;28(1):3–14.

    Article  Google Scholar 

  6. Marinos G, Eliades C, Muthusamy VR, Greenway F. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3-and 6-month study. Surg Obes Relat Dis. 2014;10(5):929–34.

    Article  Google Scholar 

  7. Densford F. BaroNova touts TransPyloric Shuttle pivotal study data. In: MassDevice Medical Network. 2018. https://www.massdevice.com/baronova-touts-transpyloric-shuttle-pivotal-study-data/. Accessed 21 July 2019.

  8. Densford F. BaroNova wins FDA nod for TransPyloric Shuttle weight loss device. In: MassDevice Medical Network. 2019. https://www.massdevice.com/baronova-wins-fda-nod-for-transpyloric-shuttle-weight-loss-device/. Accessed 21 July 2019.

  9. Sauer N, Rösch T, Pezold J, Reining F, Anders M, Groth S, Schachschal G, Mann O, Aberle J. A new endoscopically implantable device (SatiSphere) for treatment of obesity—efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes Surg. 2013;23(11):1727–33.

    Article  Google Scholar 

  10. Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, Laycock W, Adrales G, Vassiliou M, Szomstein S, Heller S. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–82.

    Article  Google Scholar 

  11. Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.

    Article  Google Scholar 

  12. Cohen RV, et al. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab. 2013;98:E279–82.

    Article  CAS  Google Scholar 

  13. Sen Gupta P, Drummond RS, Lugg ST, McGowan BM, Amiel SA, Ryder RE. One year efficacy, safety and tolerability outcomes of endoscopic duodenal exclusion using EndoBarrier as an adjunct to glucagon-like peptide-1 (GLP-1) therapy in suboptimally controlled type 2 diabetes: a randomised controlled trial. In Novel treatment for diabetes-focusing on GLP-1 and SGLT2. Endocrine Society; 2016. p. PP15–PP11. https://onlinelibrary.wiley.com/page/journal/14631326/homepage/editorialboard.html.

  14. Rohde U, Hedbäck N, Gluud LL, Vilsbøll T, Knop FK. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(3):300–5.

    Article  CAS  Google Scholar 

  15. Safety and efficacy of EndoBarrier in subjects with type 2 diabetes who are obese. In: ClinicalTrials.gov. 2016. https://clinicaltrials.gov/ct2/show/study/NCT01728116. Accessed 22 Oct 2017.

  16. Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, Schultz S, Talamini M, Horgan S. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc. 2011;25(9):3028–33.

    Article  Google Scholar 

  17. Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, Schultz S, Talamini MA, Jacobsen GR, Horgan S. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc. 2015;29(11):3298–303.

    Article  Google Scholar 

  18. The ValenTx endo bypass system in obese subjects. In: ClinicalTrials.gov. 2016. https://clinicaltrials.gov/ct2/show/NCT02954003. Accessed 22 Oct 2017.

  19. Lacy BE, Weiser K, Kennedy A. Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future? Gastroenterol Hepatol. 2008;4(4):283.

    Google Scholar 

  20. Pero R, Coretti L, Lembo F. Botulinum toxin a for controlling obesity. Toxins. 2016;8(10):281.

    Article  Google Scholar 

  21. Foschi D, Corsi F, Lazzaroni M, Sangaletti O, Riva P, La Tartara G, Bevilacqua M, Osio M, Alciati A, Bianchi Porro G, Trabucchi E. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31(4):707.

    Article  CAS  Google Scholar 

  22. Gui D, Mingrone G, Valenza V, Spada PL, Mutignani M, Runfola M, Scarfone A, Mugno M, Panunzi S. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23(5):675–80.

    Article  CAS  Google Scholar 

  23. Topazian M, Camilleri M, Enders FT, Clain JE, Gleeson FC, Levy MJ, Rajan E, Nehra V, Dierkhising RA, Collazo-Clavell ML, et al. Gastric antral injections of botulinum toxin delay gastric emptying but do not reduce body weight. Clin Gastroenterol Hepatol. 2013;11:45–50.

    Article  Google Scholar 

  24. Intragastric injections of Botox for the treatment of obesity. In: ClinicalTrials.gov. 2017. https://clinicaltrials.gov/ct2/show/NCT02035397. Accessed 22 Oct 2017.

  25. Cha R, Marescaux J, Diana M. Updates on gastric electrical stimulation to treat obesity: systematic review and future perspectives. World J Gastrointest Endosc. 2014;6(9):419–31.

    Article  Google Scholar 

  26. Lonys L, Vanhoestenberghe A, Julémont N, Godet S, Delplancke MP, Mathys P, Nonclercq A. Silicone rubber encapsulation for an endoscopically implantable gastrostimulator. Med Biol Eng Comput. 2015;53(4):319–29.

    Article  Google Scholar 

  27. Neto MG, Rajagopalan H, Becerra P, Rodriguez P, Vignolo P, Caplan J, Rodriguez L. 829 Endoscopic duodenal mucosal resurfacing improves glycemic and hepatic parameters in patients with type 2 diabetes: data from a first-in-human study. Gastroenterology. 2016;150(4):S174.

    Article  Google Scholar 

  28. Rajagopalan H, Cherrington AD, Thompson CC, Kaplan LM, Rubino F, Mingrone G, Becerra P, Rodriguez P, Vignolo P, Caplan J, Rodriguez L. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39(12):2254–61.

    Article  CAS  Google Scholar 

  29. Effect of DMR using the Revita system in the treatment of type 2 diabetes (T2D). In: ClinicalTrials.gov. 2017. https://clinicaltrials.gov/ct2/show/NCT02879383. Accessed 30 Oct 2017.

  30. Machytka E, Buzga M, Ryou M, Lautz DB, Thompson CC. 1139 Endoscopic dual-path enteral anastomosis using self-assembling magnets: first-in-human clinical feasibility. Gastroenterology. 2016;150(4):S232.

    Article  Google Scholar 

  31. Machytka E, Buzga M, Lautz DB, Ryou M, Simonson D, Thompson CC. 103 A dual-path enteral bypass procedure created by a novel incisionless anastomosis system (IAS): 6-month clinical results. Gastroenterology. 2016;150(4):S26.

    Article  Google Scholar 

  32. Machytka E, Bužga M, Zonca P, Lautz DB, Ryou M, Simonson DC, Thompson CC. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in subjects with obesity and diabetes. Gastrointest Endosc. 2017;86:904.

    Article  Google Scholar 

  33. Rossen NG, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG, Ponsioen CY. Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. World J Gastroenterol: WJG. 2015;21(17):5359.

    Article  Google Scholar 

  34. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–6.

    Article  CAS  Google Scholar 

  35. Transplantation of microbes for treatment of metabolic syndrome & NAFLD. In: ClinicalTrials.gov. 2016. https://clinicaltrials.gov/ct2/show/results/NCT02496390. Accessed 22 Oct 2017.

  36. Fecal microbiota transplantation for diabetes mellitus type II in obese patients. In: ClinicalTrials.gov. 2016. https://clinicaltrials.gov/ct2/show/NCT02346669. Accessed 22 Oct 2017.

  37. Fecal microbiota transplantation for the treatment of obesity (FMT obesity). In: ClinicalTrials.gov. 2017. https://clinicaltrials.gov/ct2/show/NCT02741518. Accessed 22 Oct 2017.

  38. Fecal microbiota transplant for obesity and metabolism. In: ClinicalTrials.gov. 2017. https://clinicaltrials.gov/ct2/show/study/NCT02530385. Accessed 22 Oct 2017.

Download references

Author information

Authors and Affiliations

  1. Massachusetts General Hospital, Department of Medicine, Boston, MA, USA

    Thomas J. Wang

  2. Harvard Medical School, Boston, MA, USA

    Thomas J. Wang & Marvin Ryou

  3. Brigham and Women’s Hospital, Division of Gastroenterology, Hepatology, and Endoscopy, Boston, MA, USA

    Marvin Ryou

Authors
  1. Thomas J. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marvin Ryou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marvin Ryou .

Editor information

Editors and Affiliations

  1. Interventional Endoscopy, Division of Gastroenterology, University of Colorado-Denver, Aurora, CO, USA

    Mihir S. Wagh

  2. Interventional Endoscopy, Division of Gastroenterology, University of Colorado-Denver, Aurora, CO, USA

    Sachin B. Wani

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wang, T.J., Ryou, M. (2020). Emerging Endoscopic Therapies for Weight Loss. In: Wagh, M., Wani, S. (eds) Gastrointestinal Interventional Endoscopy. Springer, Cham. https://doi.org/10.1007/978-3-030-21695-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-21695-5_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-21694-8

  • Online ISBN: 978-3-030-21695-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation